Making sense of the Alzheimer's drug pipeline - FierceBiotech Research

Making sense of the Alzheimer's drug pipeline - FierceBiotech Research

Novartis Has Largest Japan Exposure Among Big Pharma - Stocks To Watch Today - Barrons.com

Novartis Has Largest Japan Exposure Among Big Pharma - Stocks To Watch Today - Barrons.com

Big U.S. and European pharmaceutical companies face some short-term economic disruption from the earthquake disaster. But Leerink Swann analyst Seamus Fernandez assures that it should “be muted relative to other industries.”

On average the eight Big Pharma names Fernandez covers — Pfizer (PFE), Merck & Co. (MRK), Eli Lilly & Co. (LLY), Bristol-Myers Squibb (BMY), AstraZeneca(AZN), GlaxoSmithKline (GSK), Novartis (NVS) and Sanofi Aventis (SNY) – get 7% to 8% of their sales and 9% to 10% of their earnings per share from Japan. Bristol-Myers Squibb is the least exposed, with 3% of sales coming from Japan, while Novartis has the most exposure. The Swiss drug maker gets 10.9% of it’s pharmaceutical sales and 8% of its total revenue from Japan. GlaxoSmithKline, meanwhile, has the most bottom-line exposure, according to Fernandez. The exact figures are available in a research note he published today.

Did China Just Change Its Growth Model? - Gordon G. Chang - New Asia - Forbes

Did China Just Change Its Growth Model? - Gordon G. Chang - New Asia - Forbes

Pfizer's Biggest Shot at Lipitor 2.0 (ABT, AMGN, INCY, JNJ, MRK, PFE, RIGL)

Pfizer's Biggest Shot at Lipitor 2.0 (ABT, AMGN, INCY, JNJ, MRK, PFE, RIGL)

Six trends that will change the fundamentals of pharmaceutical distribution | Distribution, package testing, cold chain | Healthcare Packaging

Six trends that will change the fundamentals of pharmaceutical distribution | Distribution, package testing, cold chain | Healthcare Packaging

BBC - Fergus's Medical Files: Lab-grown brain cells should aid research into Alzheimer's

BBC - Fergus's Medical Files: Lab-grown brain cells should aid research into Alzheimer's

HCA Returning Three Times Cost Shows Timing Trumps Overhauls for Buyouts - Bloomberg

HCA Returning Three Times Cost Shows Timing Trumps Overhauls for Buyouts - Bloomberg

Is the New iPad 2 Worth the Cost?

Is the New iPad 2 Worth the Cost?

The number of clinicians adopting the iPad for use in medical settings is growing rapidly, as the number ofpoint-of-care apps explodes, according to a survey of nearly 950 members of the Healthcare Information and Management Systems Society and Columbia, Md.-based mobile-device management company BoxTone Inc.

Kidney Cancer Awareness

Lets look for a cure.

Cancer Awareness Ribbons, Cancer Wristbands and Cancer Gifts from Choose Hope

Cancer Awareness Ribbons, Cancer Wristbands and Cancer Gifts from Choose Hope

M&A and the Pharma Industry.

Interesting treatise on Big Pharma M&A - Please read this insightful article , we will comment further on this at a later date.

EU Approval for Xiapex - Yahoo! Finance

EU Approval for Xiapex - Yahoo! Finance: "Pfizer(NYSE: PFE - News) and Auxilium Pharmaceuticals, Inc. (NasdaqGS: AUXL - News) recently announced that the European Commission has granted marketing authorization to Xiapex for the treatment of Dupuytren's contracture in adult patients with a palpable cord.

Dupuytren’s contracture is a condition that affects the connective tissue in the palm known as palmar fascia. Auxilium Pharma estimates that approximately 13% of the European population is affected by Dupuytren’s contracture."

King Pharmaceuticals, Inc. Announces Final Results of Its Offer to Purchase Convertible Notes - Yahoo! Finance

King Pharmaceuticals, Inc. Announces Final Results of Its Offer to Purchase Convertible Notes - Yahoo! Finance

Bayer Reports Unexpected Fourth-Quarter Loss on Schering Brand Writedown - Bloomberg

Bayer Reports Unexpected Fourth-Quarter Loss on Schering Brand Writedown - Bloomberg

The drugs and chemicals conglomerate is still happy with its three divisions selling medicines, plastics and crop chemicals, Chief Executive Officer Marijn Dekkers said in a press conference today.

Divesting a unit to raise cash for an acquisition would be an “extreme option,” Dekkers said.

“Looking is a big word,” the executive said in answer to a question about whether Bayer is seeking a deal big enough to require the sale of a unit. “You don’t have to look far, because there are only 20 companies that qualify as a big acquisition. We are at the moment happy with the three subgroups we have.”

Bayer estimates the market for new blood thinners including Xarelto may exceed 10 billion euros annually. The pill’s sales may peak at more than 2 billion euros, Dekkers said.

Bayer has said it expects U.S. regulators to decide this year whether Xarelto may be used in irregular heartbeat patients. Patients with an irregular heartbeat, or atrial fibrillation, make up the biggest market for the new blood thinners, according to Bayer. The company filed for approval to sell the drug for the same patient group in Europe in January.

Is Eli Lilly a Stock for the Long Term? (LLY, MRK, NVS, PFE)

Is Eli Lilly a Stock for the Long Term? (LLY, MRK, NVS, PFE)

A great look at a Big Pharma leader.

Company	Current P/E	Dividend Yield	5-Year Net Income CAGR	1-Year Beta
Eli Lilly	7.6	5.7%	20.7%	0.5
Pfizer (NYSE: PFE)	18.9	4.2%	0.4%	0.6
Merck (NYSE:MRK)	119.7	4.6%	(28.6%)	0.5
Novartis (NYSE:NVS)	13.6	4.2%	9.82%	0.3

Takeda ARB blood pressure medication approved by FDA

Takeda ARB blood pressure medication approved by FDA

Post number 2 - testing.

Investment Research - Stock Market Research

Investment Research - Stock Market Research

Our first post; Top 5 Pharma- sales per share.